We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00986986
First Posted: September 30, 2009
Last Update Posted: December 18, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
United States Department of Defense
Information provided by (Responsible Party):
Dominic Chow, University of Hawaii
Results First Submitted: August 14, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: HIV Infections
Dyslipidemia
Endothelial Dysfunction
Intervention: Drug: extended release niacin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment was through the University of Hawaii, Hawaii Center for AIDS

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Active Drug (Extended Release Niacin) Subjects in this arm will be given 12 weeks of extended release niacin
Observation Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin

Participant Flow:   Overall Study
    Active Drug (Extended Release Niacin)   Observation
STARTED   10   10 
COMPLETED   10   9 
NOT COMPLETED   0   1 
Lost to Follow-up                0                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Active Drug (Extended Release Niacin) Subjects in this arm will be given 12 weeks of extended release niacin
Observation Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin
Total Total of all reporting groups

Baseline Measures
   Active Drug (Extended Release Niacin)   Observation   Total 
Overall Participants Analyzed 
[Units: Participants]
 10   10   20 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   10   10   20 
>=65 years   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 49.96  (11.60)   47.72  (10.81)   48.84  (10.94) 
Gender 
[Units: Participants]
     
Female   0   2   2 
Male   10   8   18 
Region of Enrollment 
[Units: Participants]
     
United States   10   10   20 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Flow-mediated Vasodilation (FMD) From Baseline to Study Week 12   [ Time Frame: Two time points (baseline and study week 12) ]

2.  Primary:   Flow Mediated Vasodilation   [ Time Frame: 12 weeks ]

3.  Secondary:   High-density Lipoprotein Cholesterol (HDL) Change From Baseline to Study Week 12   [ Time Frame: Two time points (baseline and study week 12) ]

4.  Secondary:   HDL   [ Time Frame: 12 weeks ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
  • Small sample size
  • Un-blinded pilot study
  • Increase in HDL was less than predicted in a non-HIV infected population


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dominic Chow
Organization: University of Hawaii at Manoa
phone: (808)737-2751
e-mail: dominicc@hawaii.edu


Publications of Results:

Responsible Party: Dominic Chow, University of Hawaii
ClinicalTrials.gov Identifier: NCT00986986     History of Changes
Other Study ID Numbers: ENDO
Department of Defense ( Other Grant/Funding Number: 06187003 )
First Submitted: September 29, 2009
First Posted: September 30, 2009
Results First Submitted: August 14, 2011
Results First Posted: December 18, 2012
Last Update Posted: December 18, 2012